Last reviewed · How we verify
OPC-12759 Ophthalmic suspension
OPC-12759 is an ophthalmic suspension used to treat dry eye syndrome by increasing tear production.
OPC-12759 is an ophthalmic suspension used to treat dry eye syndrome by increasing tear production. Used for Treatment of dry eye syndrome.
At a glance
| Generic name | OPC-12759 Ophthalmic suspension |
|---|---|
| Sponsor | Otsuka Pharmaceutical Co., Ltd. |
| Drug class | Ophthalmic suspension |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
OPC-12759 works by stimulating the lacrimal gland to produce more tears, which helps to alleviate dry eye symptoms. This is achieved through its mechanism of action, which involves the stimulation of the lacrimal gland's secretory function. By increasing tear production, OPC-12759 helps to restore the health and integrity of the ocular surface.
Approved indications
- Treatment of dry eye syndrome
Common side effects
- Eye irritation
Key clinical trials
- Safety Study of OPC-12759 Ophthalmic Solution (PHASE1)
- Confirmatory Study of OPC-12759 Ophthalmic Solution (PHASE3)
- Exploratory Study of OPC-12759 Ophthalmic Suspension (PHASE2)
- Dose-response Study of OPC-12759 Ophthalmic Suspension (PHASE2)
- Long Term Administration Study of OPC-12759 Ophthalmic Suspension (PHASE3)
- Confirmatory Study of OPC-12759 Ophthalmic Suspension (PHASE3)
- Late Phase 2 Study of OPC-12759 Ophthalmic Suspension (PHASE2)
- Safety and Efficacy Study of Rebamipide 2% Ophthalmic Suspension in Subjects With Dry Eye - Effects on Central Cornea (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OPC-12759 Ophthalmic suspension CI brief — competitive landscape report
- OPC-12759 Ophthalmic suspension updates RSS · CI watch RSS
- Otsuka Pharmaceutical Co., Ltd. portfolio CI